AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Fulgent Genetics, Inc.
Video analysis: FLGT
All videosNo video analysis for this stock yet. Request one from our team.
News: FLGT
Hsbc Holdings PLC Purchases New Position in Fulgent Genetics, Inc. $FLGT
Hsbc Holdings PLC purchased a new stake in shares of Fulgent Genetics, Inc. (NASDAQ: FLGT) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 45,048 shares of the company's stock, valued at approximately $915,000. Hsbc Holdings PLC owned about 0.16% of Fulgent Genetics
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics Q2 Earnings Call Highlights
Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to earnings of $0.07 per share a year ago.
Fulgent Reports Second Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Results: Revenue of $85.4 million GAAP loss of $29.5 million, or $(1.05) per share Non-GAAP loss of $16.2 million, or $(0.58) per share Adjusted EBITDA loss of $17.1 million Non.
Fulgent Genetics: Strong Moves By Management Keep Me Bullish
Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Recent opportunistic share repurchases at $15.42/share and insider buying highlight management's conviction in FLGT's intrinsic value. FLGT trades below tangible book value, with net assets per share estimated at $24.09–$29, offering a margin of safety.
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer que.
